Pharming Technologies B.V., a wholly-owned subsidiary of Pharming Group N.V., declared its recommended cash offer for Abliva AB unconditional and completed the acquisition of tendered shares. At the close of the initial acceptance period on February 7, 2025, the offer had been accepted by shareholders representing approximately 87.7 percent of Abliva's total shares and votes.
Pharming decided to waive the acceptance level condition, which previously required more than 90 percent acceptance, allowing the acquisition to proceed. All other conditions for completion of the offer were satisfied.
Settlement for shares tendered up to February 7, 2025, is expected to be initiated around February 14, 2025. Pharming has extended the acceptance period until February 20, 2025, to allow remaining shareholders to tender their shares, with settlement for this period expected around February 27, 2025.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.